Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

20.00CHF
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
CHF20.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
307,338
52-wk High
CHF30.70
52-wk Low
CHF17.10

Latest Key Developments (Source: Significant Developments)

Idorsia Launches Offering Of New Shares And Convertible Bonds
Tuesday, 10 Jul 2018 11:44am EDT 

July 10 (Reuters) - Idorsia Ltd ::IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE.LAUNCHES OFFERING OF UP TO 11,912,000 NEW SHARES THROUGH AN ACCELERATED BOOKBUILDING PROCESS.OFFERING OF CHF 200 MILLION CONVERTIBLE BONDS.NET PROCEEDS WILL ALLOW TO FUND PHASE 3 DEVELOPMENT OF IDORSIA'S LATE-STAGE PIPELINE.BONDS WILL HAVE A MATURITY OF 6 YEARS.BONDS WILL BE OFFERED WITH A COUPON BETWEEN 0.50% AND 1.00%.BONDS WILL BE OFFERED WITH CONVERSION PREMIUM BETWEEN 30% AND 35% ABOVE BOOKBUILDING PRICE OF OFFER SHARES.  Full Article

Idorsia Initiates Precision - Phase 3 Study With Aprocitentan
Wednesday, 20 Jun 2018 01:00am EDT 

June 20 (Reuters) - Idorsia Ltd ::IDORSIA INITIATES PRECISION - PHASE 3 STUDY WITH APROCITENTAN FOR RESISTANT HYPERTENSION MANAGEMENT.  Full Article

Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease
Wednesday, 16 May 2018 01:00am EDT 

May 16 (Reuters) - IDORSIA LTD ::IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE.  Full Article

Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018
Thursday, 19 Apr 2018 01:00am EDT 

April 19 (Reuters) - Idorsia Ltd ::IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018.US GAAP OPERATING RESULTS IN Q1 2018: LOSS OF CHF 74 MILLION.NON-GAAP* OPERATING RESULTS Q1 2018: LOSS OF CHF 67 MILLION.OUTLOOK 2018: NON-GAAP OPERATING EXPENSES OF AROUND CHF 390 MILLION.  Full Article

Idorsia Forms Research Collaboration With Roche In Field Of Cancer Immunotherapy
Wednesday, 20 Dec 2017 01:00am EST 

Dec 20 (Reuters) - IDORSIA LTD ::IDORSIA FORMS RESEARCH COLLABORATION WITH ROCHE IN THE FIELD OF CANCER IMMUNOTHERAPY.PARTIES WILL COLLABORATE ON DISCOVERY OF PRODUCTS THROUGH FORMATION OF A JOINT COMMITTEE, CHAIRED BY IDORSIA.ROCHE WILL PAY IDORSIA AN UPFRONT PAYMENT OF CHF 15 MILLION.ROCHE CAN THEN EXCLUSIVELY LICENSE IDORSIA COMPOUNDS AND COMPOUNDS RESULTING FROM COLLABORATION, FOR FURTHER PAYMENT OF 35 MILLION.IDORSIA WILL BE ELIGIBLE TO RECEIVE ONE-TIME DEVELOPMENT AND REGULATORY MILESTONES OF UP TO CHF 410 MILLION.IDORSIA ALSO BE ENTITLED TO ONE-TIME MILESTONES BASED ON SALES THRESHOLDS, AND TIERED ROYALTIES ON ANNUAL NET SALES.  Full Article

Idorsia ‍Q3 US GAAP operating loss at CHF 68 mln
Tuesday, 24 Oct 2017 01:00am EDT 

Oct 24 (Reuters) - IDORSIA LTD :‍US GAAP OPERATING LOSS IN Q3 2017: CHF 68 MILLION / YTD* 2017: CHF 79 MILLION​.‍NON-GAAP** OPERATING LOSS IN Q3 2017: CHF 61 MILLION / YTD* 2017: CHF 71 MILLION​.‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 160-170 MILLION​.‍AT END OF Q3, IDORSIA'S LIQUIDITY AMOUNTED TO CHF 952 MILLION​.‍9MTH US GAAP NET LOSS AMOUNTED TO CHF 82 MILLION RESULTING IN A NET LOSS PER SHARE OF CHF 0.73​.  Full Article

Idorsia ‍H1 ‍US GAAP operating loss of CHF 11 million​
Thursday, 3 Aug 2017 01:00am EDT 

Aug 3 (Reuters) - IDORSIA LTD ::‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 180-190 MILLION​.‍US GAAP OPERATING LOSS IN HALF YEAR 2017: CHF 11 MILLION​.‍NON-GAAP OPERATING LOSS IN HALF YEAR 2017: CHF 10 MILLION​.H1 ‍US GAAP NET LOSS PER SHARE AMOUNTED TO CHF 0.11, BASED ON 106 MILLION OF SHARES OUTSTANDING (TIME-WEIGHTED AVERAGE)​.  Full Article

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 159 Mln

* US GAAP OPERATING RESULTS IN HY 2018: LOSS OF CHF 155 MILLION